141 results about "Renal function" patented technology

The invention provides a multi-channel one-core multi-detection integrated detection method, which is applied to the technical field of in-vitro diagnosis and comprises the following steps: acquiring time sequence original signals of blood routine, liver function and kidney function channels; obtaining a baseline stable primary signal through cross-channel baseline trend coupling and adaptive correction; adopting a machine learning model to identify interference components and performing component offset to obtain a decoupling signal; mapping the decoupling signal into a physiological parameter value and carrying out rationality test; when the low credible parameter exists, a rechecking mechanism is triggered; performing weighted fusion on the basis of the rationality test result and the recheck signal to obtain a comprehensive parameter set; and finally generating a comprehensive detection report containing the credibility score. Cooperative processing and fusion analysis of multi-channel detection signals are realized, and the accuracy and reliability of a detection result are remarkably improved through interference identification and a dynamic recheck mechanism.

The invention relates to an intelligent decision-making system for nutrition metabolism collaborative management of elderly chronic disease patients, in particular to the field of nutrition metabolism collaborative management of elderly chronic disease, which is characterized in that drug molecule characteristics and nutrient metabolism paths are dynamically integrated through a multi-modal knowledge graph, and a cross-domain associated three-dimensional knowledge network is constructed; based on a reinforcement learning real-time optimization rule confidence threshold value, the early warning sensitivity is adaptively adjusted according to the degree that the metabolic index of the patient deviates from the safety interval; the streaming conflict detection engine accurately identifies the potential risk of asynchronously input medication and diet data, and triggers graded early warning through space-time alignment and sub-graph matching; the closed-loop evolution mechanism fuses patient compliance feedback and blood potassium change trend, drives the taboo rule base to continuously and autonomously evolve under the constraint of renal function layering, and realizes personalized risk prevention and control and metabolic state collaborative optimization.

The invention relates to the technical field of medical data processing, and discloses a non-invasive hemodynamic assessment system for coronary artery stenosis degree, comprising an image acquisition module used for acquiring a coronary artery computed tomography angiography image of a patient; the physiological signal acquisition module is used for synchronously acquiring physiological signals of a patient, and the physiological signals comprise electrocardiosignals and non-invasive arterial blood pressure signals; and the data processing module is used for preprocessing and segmenting the coronary artery computed tomography angiography image. Electrocardiogram and non-invasive arterial blood pressure signals are collected through the sensor, risks and complications caused by invasive examination of traditional coronary artery radiography are avoided, the problem that patients unsuitable for invasive examination such as contrast agent allergy and renal insufficiency are difficult to evaluate is solved, the pain of the patients is relieved, and the acceptability of the patients is improved.

The invention belongs to the technical field of medicine, and particularly relates to polygonatum polysaccharide, a preparation method and application, the structural formula of the polygonatum polysaccharide is as follows: m1 + m2 = 11, n = 4; the rhizoma polygonati polysaccharide can relieve OS, inhibit inflammatory response, break vicious circle generated and activated by inflammation-OS-TGF-beta1 and block excessive activation and downstream signals of a key fibrosis factor TGF-beta1, so that renal dysfunction and renal fibrosis induced by adenine are remarkably improved, and the rhizoma polygonati polysaccharide has a good treatment effect on renal injury.

A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.

To provide a jelly composition containing spherical adsorptive carbon for improving uremic symptoms and delaying initiation of dialysis of chronic renal failure patients, which has more improved medication compliance than existing therapeutic agents.SOLUTION: The jelly composition contains spherical adsorptive carbon as an active ingredient, a gelling agent, a thickener, and spherical adsorptive carbon containing distilled water.SELECTED DRAWING: Figure 2

Disclosed herein are pyridyl compounds. Also described are specific conjugated nicorandil compounds. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the pyridyl compounds are disclosed for the treatment of diseases or conditions related to kidney or kidney functions.

This invention belongs to the field of pharmaceutical analysis, specifically relating to a method for constructing a fingerprint spectrum of Shenfushu granules. The method for constructing a fingerprint spectrum of Shenfushu granules provided by this invention features high accuracy, high stability, good repeatability, good specificity, and strong specificity. The fingerprint spectrum analysis method for Shenfushu granules, a traditional Chinese medicine preparation for treating chronic renal failure, established by this invention can not only qualitatively analyze and identify the seven chemical components contained in this preparation, but also simultaneously present the characteristic peaks of five traditional Chinese medicines in the prescription, achieving the goal of overall quality control of multiple medicinal ingredients.

The application discloses application of tomato saponin in preparation of a uric acid reducing composition and belongs to the technical field of biological medicine. The uric acid reducing composition comprises 80-240 parts of tomato saponin, 50-120 parts of momordica charantia saponin, 25-100 parts of fruit and vegetable extract, 10-20 parts of schizonepeta turczanovii extract, 10-20 parts of terminalia catappa leaf extract and 40-100 parts of soluble dietary mixture. Animal experiment verification shows that the composition can effectively reduce blood uric acid level and improve kidney function through the synergistic effect of multi-target points such as inhibition of uric acid synthesis, promotion of uric acid excretion, anti-inflammatory kidney protection and metabolic regulation, and a safe and efficient solution is provided for hyperuricemia.

The invention relates to the technical field of traditional Chinese medicines, and discloses an external traditional Chinese medicine formula for treating arthralgia with syndrome of cold-dampness obstruction, which comprises the following ingredients: 10g of cassia twig, 6g of dried ginger, 12g of lycopodium clavatum, 12g of herba lycopi, 10g of notopterygium root, 10g of radix angelicae pubescentis, 9g of loose knot, 9g of semen brassicae, 10g of rhizoma corydalis, 15g of caulis spatholobi and 10g of cortex acanthopanacis. According to the external traditional Chinese medicine formula for treating the cold-dampness arthralgia, through accurate compatibility of medicinal materials with effects of warming and dispelling cold and dampness, promoting blood circulation to remove meridian obstruction and strengthening tendons and bones, a synergistic treatment system of warming and dredging, eliminating dampness, dredging collaterals and protecting bones is formed, so that symptoms such as joint crymodynia, stiffness and the like can be quickly relieved, cold-dampness evil can be eliminated from the pathogenesis level, and qi and blood circulation of joints can be improved; by adopting a standard processing technology and an optimized preparation method, the transdermal efficiency is improved while the irritation of the medicinal materials is reduced, the medicine can directly reach the focus, the gastrointestinal tract side effect caused by oral administration is avoided, and the traditional Chinese medicine composition is particularly suitable for middle-aged and elderly people and cold-dampness blockage type arthralgia patients with poor liver and kidney functions and sensitive skin.

The invention discloses a preparation rich in polygonatum sibiricum polypeptide and application of the preparation in diabetes mellitus. The composition is prepared from rhizoma polygonati polypeptide, semeglutide, astaxanthin, an active agent and a ferroptosis mixture. Pharmacodynamic experiments show that in a diabetic mouse model, fasting blood glucose can be remarkably reduced, the serum insulin level can be increased, renal function indexes can be improved, and expression of NLRP3 inflammation pathway related proteins (NLRP3, Caspase-1 and IL-1beta) in pancreatic tissue can be remarkably inhibited. By integrating multiple mechanisms of blood glucose reduction, oxidation resistance, inflammation resistance, ferroptosis resistance and the like, multi-target collaborative intervention is realized, the pharmaceutical composition is remarkably superior to a single component in the aspects of blood glucose reduction, pancreas islet function protection and complication alleviation, and a new clinical strategy is provided for treatment of diabetes mellitus, especially type 1 diabetes mellitus.

The invention relates to the technical field of veterinary drugs, and particularly provides a veterinary carprofen injection and a preparation method thereof, the veterinary carprofen injection comprises carprofen, emodin, galuteolin, coumarin, Radix Astragali, wolfberry, Schisandra chinensis, resveratrol and other components. According to the veterinary carprofen injection, emodin and luteoloside are added for compound anti-inflammation, the dosage of carprofen is reduced, the kidney burden is relieved, meanwhile, drug resistance is not likely to be generated, radix astragali, fructus lycii and fructus schizandrae extracts are added for protecting the kidney, regulating immunity and avoiding renal function damage, and finally the effects of compound anti-inflammation and renal function damage avoiding are achieved.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

This invention discloses a class of pyrazolopyridine compounds linked by an aza-four-membered ring, or pharmaceutically acceptable salts thereof, and their applications. These compounds can serve as novel, highly selective PDE10A inhibitors for the treatment of peripheral tissue diseases, including: myocardial hypertrophy and cardiac dysfunction (heart failure), diabetes, hypertension, renal impairment and renal fibrosis, pulmonary inflammation and pulmonary fibrosis, immune dysregulation, and cancers (colon cancer, ovarian cancer, and lung cancer). Two strategies are employed to achieve high selectivity for PDE10A inhibition while simultaneously reducing the inhibitory effect on the central nervous system. First, molecular structure modification: structural optimization of the aza-four-membered ring-linked pyrazolopyridine compounds, such as increasing the ratio of N, O, and S atoms in the molecular structure to increase the polar surface area and reduce lipophilicity; and introducing hydrophilic groups to increase water solubility, thereby reducing the permeability of the compound to the blood-brain barrier (BBB). Second, targeted drug delivery to lung tissue via pharmaceutical formulation.

The invention discloses application of rosmarinic acid in preparation of a medicine or health food for preventing and treating hyperuricemia of a patient with renal insufficiency. The medicine for preventing and treating hyperuricemia of the patient with renal insufficiency is an XOD inhibitor or an ABCG2 gene expression promoter. The rosmarinic acid can significantly reduce the serum uric acid level of HUA mice induced by high purine diet, promote ABCG2-mediated intestinal uric acid excretion, and relieve HUA-induced intestinal inflammation and barrier injury by adjusting intestinal flora. The rosmarinic acid is safe and free of toxic and side effects, and has very important application prospects.

The invention relates to the technical field of biomedical detection, and particularly discloses a marker composition for diagnosing Alzheimer's disease and application of the marker composition. The marker composition comprises p-tau217 and GFAP, and can realize accurate screening of the early stage and the clinical stage of the Alzheimer's disease. The invention also provides a diagnostic reagent by using the marker composition, the reagent adopts a biotin-streptavidin amplification principle, and the detection accuracy of the biomarker can be obviously improved; meanwhile, a kit is designed based on the reagent, the partition pore plate design is adopted, and the cross contamination probability is reduced by arranging an isolation groove with a hydrophobic material. Besides, the invention further provides a system with diagnosis and correction functions, interference of hemolysis and / or renal insufficiency on Alzheimer's disease diagnosis can be eliminated, and the problem that an existing Alzheimer's disease diagnosis technology is prone to missed diagnosis and misdiagnosis is effectively solved.

The invention discloses an identification kit and an identification system for a pathogenic T cell subset of IgA nephropathy, and belongs to the technical field of nephropathy detection.According to the identification kit, the identification of the pathogenic T cell subset in peripheral blood of the IgA nephropathy is realized by adopting a fluorescent dye labeled antibody combination, and the antibody combination comprises a CD4 fluorescent antibody, a CD103 fluorescent antibody and an ITGB1 fluorescent antibody. The antibody combination designed by the invention can detect a pathogenic T cell subset in peripheral blood of IgA nephropathy, the T cell subset is in negative correlation with a renal function index eGFR, is in positive correlation with severity of E lesion and T lesion in IgA nephropathy kidney pathological injury oxford typing, and can be used as a significant predictive factor for reduction of eGFR and severity of E lesion and T lesion. The method has an important guiding value for real-time monitoring and prognosis prediction of the IgAN, and opens up a new view for clinical management of the IgAN.

The application provides application of Trapidil in preparation of a drug for preventing and / or treating doxorubicin-induced organ toxicity, and belongs to the technical field of biological medicines.The application discloses that Trapidil plays an organ protection role by activating a cAMP / PKA / CREB signal axis and driving two parallel downstream effect channels: on the one hand, up-regulating an NRF2-GPX3 positive feedback loop to inhibit doxorubicin-induced myocardial cell pyroptosis and glomerular podocyte pyroptosis; and on the other hand, activating an NRF2 / HO-1 channel to inhibit myocardial cell apoptosis and glomerular podocyte apoptosis.In-vivo and in-vitro experiments prove that Trapidil can improve doxorubicin-induced cardiac dysfunction and kidney function damage, reduce histopathological damage, reduce the level of oxidative stress, inhibit the pyroptosis and apoptosis of myocardial cells and glomerular podocytes, and does not affect the antitumor effect of doxorubicin.The application provides a new drug strategy for doxorubicin chemotherapy-induced multi-organ toxicity.

The application relates to a chronic kidney disease prediction method based on clinical information graph representation, belongs to the technical field of computer-aided diagnosis of chronic kidney disease (CKD), and aims to solve the problem of missed diagnosis caused by the fact that the kidney function index of early CKD is not obvious. The incidence of CKD is high, the early symptoms are hidden, and the disease is easy to be missed, thus developing into end-stage renal disease. Therefore, the application provides a chronic kidney disease prediction method based on clinical information graph representation. The method first extracts fundus image and clinical index features; the clinical index is fused into a clinical index joint feature through text embedding and numerical feature fusion, and the joint feature is fused with the fundus image feature through cross-modal attention; the similarity between subjects is calculated based on the fused feature, and a subject relationship graph is constructed by using an adaptive dynamic threshold mechanism; finally, a hybrid graph neural network is used for graph representation learning, pathological similarity between subjects is mined, and accurate prediction of chronic kidney disease is realized. The application can improve the detection rate of early CKD and is applied to non-invasive early screening and risk early warning.

This invention provides a novel raw material that, for cats, which exhibit unique characteristics in their kidneys compared to other mammals, can inhibit the decline in feline kidney function and improve coat condition while maintaining the form of cat food or other feeds. When using a poorly soluble soybean protein raw material with a characteristic amino acid composition of less than a glutamic acid (Glu) to leucine (Leu) mass ratio of 2, and an NSI of 10%–60%, the decline in feline kidney function can be inhibited and coat condition improved through small-scale intake. This raw material can also be obtained as undigested residue from the soybean peptide manufacturing process.

The application relates to the technical field of kidney stone operation management, and discloses a multi-dimensional management system based on clinical data of kidney stone operation. A preoperative data integration module of the system receives and integrates image data from CT, ultrasound, X-ray and other devices, and generates a three-dimensional stone distribution model through spatial registration. A surgical risk assessment module extracts parameters such as stone volume, density and position based on the model, combines physiological indicators and historical operation data of the patient, and calculates a surgical difficulty coefficient and a complication probability. An intraoperative real-time monitoring module collects endoscope video, laser parameter and flushing liquid pressure data, and updates the stone crushing state and residual volume in real time. A tissue damage early warning module analyzes the laser energy distribution and the tissue contact time, assesses the thermal damage risk and generates a safe operation boundary. A postoperative recovery prediction module integrates the operation data and the metabolic characteristics of the patient, and predicts the stone clearance rate and the recovery progress of the kidney function.

The application discloses application of DNA methyltransferase inhibitors in preparation of drugs for treating polycystic kidney disease. Preferably, the DNA methyltransferase inhibitor is decitabine or azacitidine, and the polycystic kidney disease is polycystic kidney disease caused or aggravated by mTOR activation. The application uses Tsc2 knockout mouse embryo fibroblasts MEF and Tsc2 kidney-specific knockout mice, finds that after treatment of the DNA methyltransferase inhibitor decitabine, cell proliferation is inhibited, polycystic kidney disease of the mice is relieved, and kidney function is partially recovered. The application provides a new and effective technical means for treatment of polycystic kidney disease.

The invention belongs to the technical field of food processing and medicine preparation, and particularly relates to a uric acid reducing composition and a preparation and application thereof. According to the invention, the functional active components capsaicin and quercitrin in hot pepper are found for the first time and both have prevention and improvement effects on hyperuricemia. The two medicines can inhibit activity of purine metabolism key enzyme, promote excretion of uric acid, reduce oxidative stress and inflammatory factor level of a body, delay pathological process of hyperuricemia and protect liver and kidney functions, and do not cause liver and kidney injury and other side effects after long-term use. Moreover, the uric acid reducing effect of cooperative intervention of the capsaicin and the quercitrin, the improvement effect on hyperuricemia and the molecular mechanism of the hyperuricemia are clarified from multiple aspects, and it is proved that the capsaicin and the quercitrin are compounded according to a certain proportion to achieve synergistic interaction. Capsaicin and quercitrin are taken as active ingredients and can be used for developing health care products and medicines with the uric acid reducing effect.

The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.

The invention discloses application of a calcimimetic agent in preparation of a medicine for treating autosomal dominant polycystic kidney disease. Pax8rtTA is adopted; tetOCre is taken as a starting material; after a Pkd1fl / fl mouse model is treated by a calcimimetic cinacalcet, by inhibiting secretion of parathyroid hormone, abnormal activation of ciliary positioning Pth1r is reduced, the progress of the polycystic kidney disease is delayed, and the medicine can remarkably delay cyst growth, improve related indexes of renal functions and has a significant clinical application prospect. The abnormal proliferation of cyst epithelial cells and the interstitial fibrosis process of the kidney are effectively inhibited.

The invention belongs to the technical field of chemical drugs, and particularly relates to application of a traditional Chinese medicine composition in preparation of drugs for treating recurrent clostridium difficile infection.The traditional Chinese medicine composition is prepared from 10-50 g of fresh ginger, 3-20 g of honey-fried licorice roots, 5-30 g of ginseng, 3-20 g of dried ginger, 3-30 g of scutellaria baicalensis, 3-30 g of pinellia ternate, 3-15 g of coptis chinensis and 10-30 g of Chinese dates. The traditional Chinese medicine composition is excellent in clinical effect, and in sample research on high-risk crowds such as old people and immunosuppression CDI relapse patients, the treatment scheme of the vancomycin combined with the ginger heart-fire purging decoction is remarkably superior to vancomycin single-drug treatment in the aspect of continuous clinical response rate at the main curative effect end point. This benefit is achieved mainly by reducing the recurrence rate of CDI by more than 60%. The combined scheme shows a robust curative effect in key subgroups such as the elderly and immunosuppressive subgroups, is good in safety, does not increase extra adverse event risks, and particularly does not observe renal function impairment.

The present application relates to the technical field of medical information processing, in particular to an abnormal event automatic classification and recording method in a kidney disease follow-up system, comprising collecting kidney function parameters and symptom codes, identifying abnormal sequences, extracting time anchor points and characteristic identifiers, calculating flip frequency and amplitude, constructing a feature vector to evaluate risk and generating event classification records. In the present application, by constructing an abnormal trigger ordered sequence and extracting anchor points to determine composite features, combining symptom flip frequency to construct a persistence intensity coefficient, quantifying disease complexity from the dimensions of time evolution and etiology coupling, using a multi-dimensional feature vector to fuse physiological amplitude and statistical characteristics, obtaining disease risk probability values through weighted calculation, realizing the transition from qualitative classification to quantitative risk grading, solving the false alarm and missed alarm problems caused by single index determination, providing dynamic diagnosis basis containing risk level for clinical, significantly improving the recognition accuracy and intervention timeliness of the hidden deterioration trend in kidney disease follow-up.

The invention belongs to the field of traditional Chinese medicines, and provides a medicine for treating or adjunctively treating chronic renal failure, which is prepared from the following raw material medicines in parts by weight: 5-15 parts of ginseng; 5-20 parts by weight of bighead atractylodes rhizome; 10-30 parts by weight of wrinkled gianthyssop herb; 10-30 parts by weight of amomum tsao-ko; 5-20 parts by weight of Chinese angelica; 5-25 parts by weight of ligusticum wallichii; 5-20 parts by weight of rheum officinale; 5-20 parts by weight of curcuma zedoary; 5-20 parts by weight of rhizoma sparganii; and 10-30 parts by weight of Radix Astragali. The components in the medicine provided by the invention are reasonable in compatibility and synergistic in effect, can relieve progressive deterioration of renal function and improve biochemical indexes of patients, has an obvious treatment effect on chronic renal failure, does not have obvious toxic or side effects, and is very suitable for popularization and application.